SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor
Year: 2017
Type: article
Source: Cardiovascular Drugs and Therapy
Authors: Yumei Ye, Mandeep Bajaj, Hsiu-Chiung Yang, Jose R. Perez-Polo, Yochai Birnbaum
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: AstraZeneca
OpenAlex ID: W2608233061